Journal article
Intravenous secretin for autism spectrum disorders (ASD).
K Williams, JA Wray, DM Wheeler
Cochrane Database of Systematic Reviews Online | Published : 2012
Abstract
In 1998 secretin, a gastrointestinal hormone, was suggested as an effective treatment for autism spectrum disorders (ASD) based on anecdotal evidence. To assess whether intravenous secretin improves the core features of ASD, other aspects of behaviour or function such as self-injurious behaviour, and the quality of life of affected individuals and their carers. We also assessed whether secretin causes harm. This is an updated version of our review of this topic originally published in 2005. We searched CENTRAL (2010 Issue 1), MEDLINE (1950 to January 2010) , EMBASE (1980 to 2010 Week 2), PsycINFO (1806 to 2010 Week 2), CINAHL (1938 to January 2010), ERIC (1966 to January 2010), Sociological ..
View full abstractGrants
Funding Acknowledgements
Internal sources Small Grants Scheme of the Children's Hospital at Westmead, Australia. External sources Financial Markets Foundation for Children, Australia. John A Wray - was involved in two trials included within this review (Wray; Levy 2003). Dr Wray has declared he delivered a previous testimony for inclusion of risperidone for children with autism on Australia's Public Medicines Prescription Benefit Scheme. Airfares and accommodation were paid for by Janssen Pharmaceutical. The authors would like to thank those trialists who provided us with information and debate about secretin. We thank Drs Julian Higgins, Alex Sutton, Jon Deeks, Jenny Peat and Andrew Hayen for their advice and assistance with methods and meta-analysis. We commend the tireless efforts of the Cochrane Developmental, Psychosocial and Learning Problems Group for their help with literature searching, review and editing, in particular the support of Dr Jane Dennis. Danielle Wheeler was funded by the Small Grants Scheme of The Children's Hospital at Westmead and the Financial Markets Foundation for Children.